Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $19.75
  • 50 Day Moving Average: $18.90
  • 200 Day Moving Average: $15.49
  • 52-Week Range: $45,121,000.00 - $10.50
  • Trailing P/E Ratio: 65.16
  • Foreward P/E Ratio: 35.21
  • P/E Growth: 2.17
  • Market Cap: $905.58M
  • Outstanding Shares: 45,121,000
  • Beta: 1.83
  • Net Margins: 5.19%
  • Return on Equity: 4.71%
  • Return on Assets: 3.51%
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 2.76%
  • Quick Ratio: 1.42%
Additional Links:
Companies Related to Amphastar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $19.80 (1.35% downside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateFirmActionRatingPrice TargetDetails
9/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$22.00 -> $23.00View Rating Details
8/9/2016Jefferies GroupBoost Price TargetBuy$16.00 -> $19.00View Rating Details
8/9/2016BMO Capital MarketsReiterated RatingHold$17.00View Rating Details
8/9/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $22.00View Rating Details
3/15/2016Raymond James Financial Inc.Lower Price Target$23.00 -> $18.00View Rating Details
2/19/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
(Data available from 9/26/2014 forward)


Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.08)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.07)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014($0.11)$0.02ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Current Year EPS Consensus Estimate: $0.37 EPS
Next Year EPS Consensus Estimate: $0.57 EPS


Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Ownership Percentage: 29.30%
Institutional Ownership Percentage: 35.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateHeadline logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9. ... - Nasdaq (NASDAQ:AMPH) - September 24 at 8:48 AM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9.3 million of Shares (NASDAQ:AMPH) - September 23 at 3:54 PM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9.' million of Shares - (NASDAQ:AMPH) - September 23 at 8:18 AM logoAmphastar Pharmaceuticals Inc (AMPH) CEO & Chief Science Officer Jack Y. Zhang Sold $9. ... (NASDAQ:AMPH) - September 23 at 8:18 AM logoAmphastar Pharmaceuticals Inc. (AMPH) Rose To A New High After S&P Change (NASDAQ:AMPH) - September 21 at 4:23 PM logoAmphastar Pharmaceuticals Reaches Analyst Target Price (NASDAQ:AMPH) - September 21 at 4:23 PM
News IconWhy Amphastar Pharmaceuticals, Inc. is Soaring Today | Fox Business - Fox Business (NASDAQ:AMPH) - September 21 at 9:21 AM logo18 Biggest Mid-Day Gainers For Tuesday - Benzinga (NASDAQ:AMPH) - September 20 at 3:30 PM logoWhy Amphastar Pharmaceuticals, Inc. is Soaring Today - Motley Fool (NASDAQ:AMPH) - September 20 at 3:30 PM logoWhy Amphastar Pharmaceuticals, Inc. is Soaring Today (NASDAQ:AMPH) - September 20 at 3:29 PM logoStocks Higher Ahead Of Fed; Surging Biotechs Give Nasdaq A Boost (NASDAQ:AMPH) - September 20 at 3:29 PM logoTeva Presents Top-Line Data from Huntington Disease Study (NASDAQ:AMPH) - September 20 at 9:24 AM logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Brokerage Rating Update At 1.2 - Investor Newswire (NASDAQ:AMPH) - September 19 at 4:26 PM logoAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Posted A Surprise Factor Of 800 Percent - Investor Newswire (NASDAQ:AMPH) - September 17 at 3:29 PM
News IconAllergan paying $639 million for Vitae Pharmaceuticals (NASDAQ:AMPH) - September 16 at 12:10 PM
News IconAnalyst Projections and Growth Recap for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Post News (NASDAQ:AMPH) - September 15 at 8:38 PM
News IconAnalysts Take: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:AMPH) - September 13 at 3:29 PM
News IconPiper Jaffray Cos. Reiterates Overweight at Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) - BNB Daily (blog) (NASDAQ:AMPH) - September 10 at 3:26 PM
News IconPlacing Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Under the Microscope - Post News (NASDAQ:AMPH) - September 9 at 3:27 PM
News IconStock Slipping Down Over the Past Five Trading Sessions: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - National Daily Press (NASDAQ:AMPH) - September 9 at 3:27 PM logo5 Stocks with Favorable Liquidity Ratios for High Returns (NASDAQ:AMPH) - September 8 at 11:16 AM
News IconRhode Island, Amphastar extend Narcan rebate program (NASDAQ:AMPH) - September 7 at 8:37 PM
News IconHealth Workers Ration Opioid Overdose Antidote Amid Price Hikes (NASDAQ:AMPH) - September 6 at 8:35 PM logoAmphastar Pharmaceuticals to Present at the 2016 Wells Fargo Healthcare Conference - GlobeNewswire (press release) (NASDAQ:AMPH) - September 2 at 3:30 PM
News IconOfficials Say More Needs To Be Done To Combat Opioid Epidemic (NASDAQ:AMPH) - September 1 at 11:57 AM logoAmphastar Pharmaceuticals to Present at the 2016 Wells Fargo Healthcare Conference (NASDAQ:AMPH) - September 1 at 11:57 AM logoETF’s with exposure to Amphastar Pharmaceuticals, Inc. : September 1, 2016 (NASDAQ:AMPH) - September 1 at 11:57 AM
News IconPublic access to life-saving overdose drug expands to 79 Ohio counties (NASDAQ:AMPH) - August 30 at 11:29 AM
News IconAttorney general reminds law enforcement of naloxone rebates (NASDAQ:AMPH) - August 29 at 4:06 PM
News IconLaw enforcement officers reminded about Naloxone rebates (NASDAQ:AMPH) - August 28 at 8:16 AM
News IconDeWine reminds law enforcement of Naloxone rebates (NASDAQ:AMPH) - August 27 at 3:27 PM
News IconA-G pushing naloxone reimbursement (NASDAQ:AMPH) - August 27 at 3:27 PM
News IconBiotechnology Stocks: Tiny Biotech Stock Poised to Surge (NASDAQ:AMPH) - August 27 at 8:19 AM
News IconNaloxone rebates help some first responders (NASDAQ:AMPH) - August 26 at 3:29 PM logoIs Amphastar Pharmaceuticals (AMPH) a Great Growth Stock? (NASDAQ:AMPH) - August 24 at 11:45 AM
News IconAmphastar Pharmaceuticals, Inc.'s (AMPH): Prominent Stock of Market - Hot Stocks Point (NASDAQ:AMPH) - August 23 at 8:46 PM logoStocks Tread Water; Facebook Tries To Retake Short-Term Line (NASDAQ:AMPH) - August 22 at 3:31 PM logoETF’s with exposure to Amphastar Pharmaceuticals, Inc. : August 19, 2016 (NASDAQ:AMPH) - August 19 at 4:06 PM logoAMPHASTAR PHARMACEUTICALS, INC. Financials (NASDAQ:AMPH) - August 18 at 3:37 PM
News Icon1 usd to czk Trade-ideas_ amphastar pharmaceuticals (amph) is today’s weak on high relative volume stock – thestreet inr to usd exchange rate (NASDAQ:AMPH) - August 18 at 11:53 AM
News IconWill the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor? (NASDAQ:AMPH) - August 17 at 11:42 AM logoWhy Amphastar Pharmaceuticals (AMPH) Could Be Positioned for a Surge (NASDAQ:AMPH) - August 17 at 11:42 AM logoAmphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:AMPH) - August 12 at 12:02 PM
News IconAmphastar Pharmaceuticals Inc 23.6% Potential Upside Now Implied by Needham (NASDAQ:AMPH) - August 11 at 9:21 PM logoEdited Transcript of AMPH earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:AMPH) - August 10 at 3:50 PM logoIs This the Right Time to Add Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to Your Portfolio? - Street Report (NASDAQ:AMPH) - August 10 at 10:27 AM logoTop 5 Pharmaceutical Stocks of 2016 (ABBV, JNJ) (NASDAQ:AMPH) - August 9 at 4:34 PM logoAmphastar Pharmaceuticals : beats 2Q profit forecasts (NASDAQ:AMPH) - August 9 at 12:14 PM logoAMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:AMPH) - August 9 at 12:14 PM logoAmphastar Pharmaceuticals Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended ... - The Wall Street Transcript (NASDAQ:AMPH) - August 8 at 8:57 PM


Amphastar Pharmaceuticals (NASDAQ:AMPH) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff